Twist Bioscience (TWST) Officer Sell-to-Cover Transaction Details

Rhea-AI Filing Summary

Robert F. Werner, Chief Accounting Officer of Twist Bioscience Corp (TWST), reported a non-discretionary sale of shares on 08/21/2025 to satisfy tax withholding on vesting restricted stock units. The Form 4 shows a sale of 238 shares at a price of $25.964 per share, leaving the reporting person with 49,542 shares beneficially owned after the transaction. The filing clarifies this was a mandatory "sell to cover" required by the issuer's equity incentive plan and not an independent trading decision by the reporting person.

Positive

• Transaction disclosed promptly on Form 4, demonstrating compliance with Section 16 reporting requirements
• Sale was non-discretionary (a mandatory "sell to cover" for tax withholding), reducing likelihood it signals a change in the officer's view

Negative

• Beneficial ownership decreased by 238 shares following the sale
• Filing provides limited context beyond the sell-to-cover explanation (no market commentary or broader compensation detail)

Insights

Securities Analyst

TL;DR: A routine sell-to-cover transaction by an officer; non-discretionary and limited in size.

The Form 4 documents a sale of 238 shares at $25.964 to satisfy tax withholding on vested RSUs. This type of transaction is common when companies require withholding at vesting and does not indicate a voluntary disposition for cash or a change in investment view. The remaining reported beneficial ownership of 49,542 shares provides context on the officer's continued stake. No derivative transactions or additional material events are reported.

Corporate Governance Expert

TL;DR: Filing shows compliance with equity-plan withholding rules; no governance red flags evident.

The submission, signed by an attorney-in-fact, notes the sale was mandated by the issuer's election under its equity incentive plans. That clarity supports transparency and adherence to plan terms. There are no indications of rule 10b5-1 trading plans or other arrangements disclosed. The disclosure is narrowly focused and fulfills Section 16 reporting requirements.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

WERNER ROBERT F.

(Last) (First) (Middle)

C/O TWIST BIOSCIENCE CORPORATION

681 GATEWAY BLVD

(Street)

SOUTH SAN FRANCISCO CA 94080

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Twist Bioscience Corp [ TWST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Accounting Officer

3. Date of Earliest Transaction (Month/Day/Year)
08/21/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/21/2025		S		238(1)	D	$25.964	49,542	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of Restricted Stock Units. These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

Remarks:

	/s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner	08/25/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did Robert F. Werner report on Form 4 for TWST?

The Form 4 reports a sale of 238 shares on 08/21/2025 at a price of $25.964 per share to satisfy tax withholding on vested restricted stock units.

Was the sale by the Twist Bioscience officer discretionary?

No. The filing states the sale was a mandatory "sell to cover" required by the issuer's equity incentive plan to satisfy tax withholding obligations.

How many TWST shares does the reporting person own after the transaction?

After the reported sale, the reporting person beneficially owns 49,542 shares.

Does the Form 4 indicate any derivative transactions or 10b5-1 plan?

No. The filing shows only a non-derivative sale to cover taxes and does not disclose any derivative trades or a 10b5-1 trading plan.

Who signed the Form 4 filing for Robert F. Werner?

The Form 4 is signed by /s/ Kendra Fox, as Attorney-in-Fact for Robert F. Werner with a signature date of 08/25/2025.